复方苦参注射液对直肠癌患者的Th17细胞和IL-17因子的影响以及远期临床疗效

The effect of complex sophorae injection on Th17 cells and IL-17 in patients with rectal cancer and its long-term clinical efficacy

[目的]观察复方苦参注射液对直肠癌患者的Th17细胞和IL-17因子的影响,并分析其远期临床疗效。[方法]选择2012年8月~2015年2月我院诊治的直肠癌患者136例,使用数字法随机分为对照组和复方苦参注射液观察组,每组68例。辅助性T细胞17(Th17)使用流式细胞仪检测,白细胞介素17(IL-17)使用ELISA法检测。比较2组近远期临床疗效以及不良反应。[结果]2组治疗前Th17细胞比例和IL-17表达差异无统计学意义(P>0.05),治疗后观察组Th17细胞比例和IL-17表达均显著低于对照组(P<0.05)。化疗4个疗程结束后,观察组有效率和控制率分别为60.3%(41/68)和91.2%(55/68),显著高于对照组的44.1%(30/68)和80.9%(55/68)(P<0.05)。观察组不同级别的白细胞减少、贫血、血小板减少、神经系统毒性、胃肠道反应、口腔黏膜炎发生率显著低于对照组(P<0.05)。观察组中位生存时间10.7个月,肿瘤进展时间为9.4个月,1年生存率为79.4%(54/68);对照组中位生存时间8.7个月,肿瘤进展时间为8.1个月,1年生存率为67.6%(46/68),2组间差异有统计学意义(P<0.05)。[结论]复方苦参注射液联合FOLFOX4方案显著降低了直肠癌患者Th17细胞比例和IL-17表达,提高了近远期疗效,并降低了化疗药物的临床毒副反应。

[Objective] To observe the effect of complex sophorae injection on Thl7 cells and IL-17 in patients with rectal cancer and explore its long-term clinical efficacy. [Methods] 136 patients with rectal cancer were selected in this study. The patients were divided into FOLFOX4 control group（n= 68）and com- plex sophorae injection combined with FOLFOX4 observation group（n= 68）. Th17 cells were detected by flow cytometry,and IL-17 was detected using the ELISA assay. The clinical efficacy and adverse reactions were compared between the two groups. I-Results]There was no significant difference of Thl7 cells and IL- 17 between the two groups before treatment（P〉0.05）. After treatment,Thl7 cells and IL-17 in observa- tion group was lower than that in control group（P〈0.05）. After four cycles of treatment,the effective rate and control rate in observation group was 60.3% （41/68） and 91.2% （55/68）, which was higher than that of 44.1%（30/68）and 80.9%（55/68）in control group（P〈0.05）. The different levels of white blood cells decrease, anemia, thrombocytopenia, nervous system toxicity, gastrointestinal tract reaction, oral mucositis in- cidence in observation group was lower than that in control group（P〈0.05）. In observation group,the me-dian survival time was 10. 7 months, time to tumor progression was 9.4 months, 1 year survival rate was 79.4%（54/68） ,and in control group,the median survival time was 8.7 months,time to tumor progression was 8.1 months, 1 year survival rate was 67.6 % （46/68）. There was significant difference between the two groups（P〈0.05）. [Conclusion]Complex sophorae injection combined with FOLFOX4 regimen can reduce Th17 cells and IL-17 in patients with rectal cancer,improve short or long-term clinical outcomes,and reduce the clinical toxicity of chemotherapy drugs.